



## OPEN ACCESS

EDITED AND REVIEWED BY  
Xianquan Zhan,  
Shandong First Medical University,  
China

## \*CORRESPONDENCE

Hai-Feng Qin  
✉ hifo@263.net  
Yi Hu  
✉ huyi301zlx@sina.com

†These authors have contributed  
equally to this work

## SPECIALTY SECTION

This article was submitted to  
Cancer Molecular Targets  
and Therapeutics,  
a section of the journal  
Frontiers in Oncology

RECEIVED 01 December 2022

ACCEPTED 05 December 2022

PUBLISHED 13 December 2022

## CITATION

Wang S-S, Wang F, Zeng Z, Gao F,  
Liu H-H, Wang H-N, Hu Y and Qin H-F  
(2022) Corrigendum: Case report: A  
novel intergenic *MIR4299/MIR8070-  
RET* fusion with RET amplification and  
clinical response to pralsetinib in a lung  
adenocarcinoma patient.  
*Front. Oncol.* 12:1113289.  
doi: 10.3389/fonc.2022.1113289

## COPYRIGHT

© 2022 Wang, Wang, Zeng, Gao, Liu,  
Wang, Hu and Qin. This is an open-  
access article distributed under the  
terms of the [Creative Commons  
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,  
distribution or reproduction in other  
forums is permitted, provided the  
original author(s) and the copyright  
owner(s) are credited and that the  
original publication in this journal is  
cited, in accordance with accepted  
academic practice. No use,  
distribution or reproduction is  
permitted which does not comply with  
these terms.

# Corrigendum: Case report: A novel intergenic *MIR4299/MIR8070-RET* fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Sha-Sha Wang<sup>1†</sup>, Fang Wang<sup>2†</sup>, Zhen Zeng<sup>1</sup>, Fang Gao<sup>1</sup>,  
Huan-Huan Liu<sup>3</sup>, Hui-Na Wang<sup>3</sup>, Yi Hu<sup>1\*</sup> and Hai-Feng Qin<sup>1\*</sup>

<sup>1</sup>Department of Oncology, Chinese People's Liberation Army General Hospital, Beijing, China, <sup>2</sup>Department of Internal Medicine, OASIS International Hospital, Beijing, China, <sup>3</sup>Department of Medicine, Acornmed Biotechnology Co., Ltd., Beijing, China

## KEYWORDS

RET intergenic fusion, pralsetinib, lung adenocarcinoma, novel intergenic, tyrosine kinase inhibitors

## A Corrigendum on:

Case Report: A novel intergenic *MIR4299/MIR8070-RET* fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient.

By Wang S-S, Wang F, Zeng Z, Gao F, Liu H-H, Wang H-N, Hu Y and Qin H-F (2022) *Front. Oncol.* 12:929763. doi: 10.3389/fonc.2022.929763

In the published article, there were two errors made in the Case representation section regarding the dose of pralsetinib.

Firstly, a correction has been made to Case representation, Paragraph 1 on Page 2 of the article. The sentence “He was subsequently treated with pralsetinib (600 mg orally once daily)” has been corrected to “He was subsequently treated with pralsetinib (400 mg orally once daily)”.

Secondly, a correction has been made to Case representation, Paragraph 1 on Page 3. The sentence “Therefore, he was considered to achieve a partial response (PR) according to RECIST 1.1 criteria and continued to receive pralsetinib (600 mg orally once daily)” has been corrected to “Therefore, he was considered to achieve a partial response (PR) according to RECIST 1.1 criteria and continued to receive pralsetinib (400 mg orally once daily)”.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.